Rajveer Sachdev, MD
Family Medicine · Pomona, NYNPI 1275624660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,258 of the $210,559 with a category attached, or 73.7%. Lilly USA, LLC accounts for 91.7% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $91,520, more than ten times the $1,333 reported in 2019. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,237 payments — averaging $170.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$193K
- Corcept Therapeutics$3K
- Novo Nordisk$3K
- AstraZeneca$2K
- AbbVie$1K
- Bayer$1K
- plus $6K from 29 others
What the payments were for
- Consulting fees$9000%
- Speaking & faculty fees$155,25874%
- Travel & lodging$32,36515%
- Food & beverage$21,98710%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 458 | $193,179 |
| Corcept Therapeutics | 25 | $3,214 |
| Novo Nordisk | 186 | $2,903 |
| AstraZeneca | 114 | $2,489 |
| AbbVie(2 entities) | 89 | $1,407 |
| Bayer | 41 | $1,160 |
| Boehringer Ingelheim | 53 | $1,033 |
| Pfizer | 48 | $968 |
| GSK | 48 | $857 |
| Exact Sciences | 16 | $344 |
| Novartis | 15 | $341 |
| Kowa Pharmaceuticals America, Inc. | 17 | $313 |
| Currax Pharmaceuticals LLC | 20 | $305 |
| Sanofi-aventis U.S. LLC | 15 | $300 |
| Merck | 17 | $255 |
| Johnson & Johnson | 14 | $249 |
| Axsome Therapeutics, Inc. | 5 | $226 |
| Arbor Pharmaceuticals, Inc. | 13 | $224 |
| Amgen(2 entities) | 8 | $161 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| Azurity Pharmaceuticals, Inc. | 4 | $76 |
| Lundbeck LLC | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Gilead | 3 | $48 |
| Genentech USA, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Biogen | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$210,559 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $134,334 |
| OzempicSemaglutide | 29 | $68,347 |
| KerendiaFinerenone | 41 | $65,958 |
| FarxigaDapagliflozin Propanediol | 51 | $65,390 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $43,395 |
| JardianceEmpagliflozin | 27 | $42,954 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $18,135 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,817 |
| Rosuvastatin Calcium | 209 | $2,765 |
| Levothyroxine Sodium | 102 | $1,892 |
| Atorvastatin Calcium | 110 | $1,186 |
| Valsartan | 42 | $1,121 |
| Metoprolol Succinate | 66 | $984 |
| Gabapentin | 59 | $853 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $193,179 | $134,33481 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $1,033 | $86,34959 claims |
| Novo NordiskOzempic | $2,903 | $68,34729 claims |
| BayerKerendia | $1,160 | $65,95841 claims |
| AstraZenecaFarxiga | $2,489 | $65,39051 claims |
| MerckJanumet | $255 | $6,81711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Pomona
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Sean FentonStaten Island$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.